A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese Participants

Launched by UNIQUITY ONE (UNI) · Mar 4, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called Solrikitug to see how safe it is and how well it is tolerated when given as an injection under the skin. The trial will involve healthy volunteers, both Japanese and non-Japanese, to learn more about how the body processes this medication. It's important to note that this study is still in the planning stage and has not started recruiting participants yet.

To be eligible for this trial, participants need to be generally healthy adults aged 18 to 55 years, with no serious medical issues. They will need to agree to use contraception during the study and be able to provide informed consent, meaning they understand the study and its requirements. Participants can expect to undergo medical evaluations, including physical exams and lab tests, to ensure they are healthy enough to join the study. This trial aims to ensure that Solrikitug is safe for use in future studies and treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • At the time of initial screening, in general good health (age 18 to 55 years);
• • Participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring
• • Participant must agree to use contraception during the treatment period and until follow-up
• • Capable of giving signed informed consent which includes compliance with the requirements and restrictions of the study
• Exclusion Criteria:
• • Pregnancy or breastfeeding during the study
• • Chronic infection
• • Treatment with prohibited medications.